The Company is founded, and the midazolam film project is initiated based on a solid foundation of preliminary in vivo data and pharmaceutical film development experience.
First seed funding.
National phase entry for the midazolam film patent application.
Collaboration started with regulatory advisory firm SOFUS (Stockholm), now ProPharma Group.
Regulatory advice for the midazolam film project received from the Swedish MPA and the UK’s MHRA.
Completion of a series of twenty in-depth interviews with neurologists, parents and other caretakers.
Collaboration for the midazolam film project initiated with clinical CRO Quinta-Analytica (Prague).
Series A funding.
Scientific Advice Meeting for the midazolam film project held with the Swedish MPA. Exclusive collaboration agreement
for the midazolam film project signed with GMP manufacturer AdhexPharma (Dijon).
Advisory meeting with the Swedish pricing & reimbursement agency TLV regarding the midazolam film product. The EPO announces a decision-to-grant for the midazolam film patent application.
The midazolam film patent application is validated (approved) in ten EPO member states. Pre-study for a second project is started, aimed at new film product intended for the US market.